Immune Design Corp. Company Profile (NASDAQ:IMDZ)

About Immune Design Corp. (NASDAQ:IMDZ)

Immune Design Corp. logoImmune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMDZ
  • CUSIP: N/A
  • Web:
  • Market Cap: $133.22 million
  • Outstanding Shares: 25,619,000
Average Prices:
  • 50 Day Moving Avg: $10.13
  • 200 Day Moving Avg: $8.58
  • 52 Week Range: $4.50 - $13.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.24
  • P/E Growth: -0.57
Sales & Book Value:
  • Annual Revenue: $16.46 million
  • Price / Sales: 8.09
  • Book Value: $2.87 per share
  • Price / Book: 1.81
  • EBITDA: ($47,730,000.00)
  • Net Margins: -324.33%
  • Return on Equity: -59.14%
  • Return on Assets: -49.55%
  • Current Ratio: 5.21%
  • Quick Ratio: 5.17%
  • Average Volume: 247,383 shs.
  • Beta: 2.77
  • Short Ratio: 7.87

Frequently Asked Questions for Immune Design Corp. (NASDAQ:IMDZ)

What is Immune Design Corp.'s stock symbol?

Immune Design Corp. trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design Corp.'s earnings last quarter?

Immune Design Corp. (NASDAQ:IMDZ) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.11. The firm earned $0.73 million during the quarter, compared to analysts' expectations of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. View Immune Design Corp.'s Earnings History.

When will Immune Design Corp. make its next earnings announcement?

Immune Design Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Immune Design Corp..

Where is Immune Design Corp.'s stock going? Where will Immune Design Corp.'s stock price be in 2017?

4 brokerages have issued 1 year price targets for Immune Design Corp.'s shares. Their predictions range from $10.00 to $20.00. On average, they anticipate Immune Design Corp.'s share price to reach $16.00 in the next year. View Analyst Ratings for Immune Design Corp..

What are analysts saying about Immune Design Corp. stock?

Here are some recent quotes from research analysts about Immune Design Corp. stock:

  • 1. According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 is being evaluated for soft tissue sarcoma and G100 for Merkel cell carcinoma , follicular non-Hodgkin Lymphoma and sarcoma. The company expects to provide data this year on both the lead product candidate from both monotherapy and combination studies to support their potential registration paths towards commercialization. We are positive on its strategic agreements with companies like Sanofi, Roche, and Merck, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. The company’s shares have outperformed the Medical-Drugs industry year to date. Loss estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Who are some of Immune Design Corp.'s key competitors?

Who are Immune Design Corp.'s key executives?

Immune Design Corp.'s management team includes the folowing people:

  • Edward E. Penhoet Ph., D., Independent Chairman of the Board
  • Carlos V. Paya M.D., Ph.D., President, Chief Executive Officer, Director
  • Stephen R. Brady J.D., Executive Vice President, Strategy & Finance
  • Sergey Yurasov M.D., Ph.D., Senior Vice President, Clinical Development, and Chief Medical Officer
  • Jan Henrik Ter Meule M.D., Chief Scientific Officer
  • Melanie Morrison, Vice President - Oncology Platform Leader
  • Heidi Petersen, Vice President - Regulatory Affairs
  • Wayne R. Gombotz Ph.D., Chief Development Officer
  • David Baltimore Ph.D., Independent Director
  • Franklin M. Berger, Independent Director

How do I buy Immune Design Corp. stock?

Shares of Immune Design Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Design Corp.'s stock price today?

One share of Immune Design Corp. stock can currently be purchased for approximately $5.20.

MarketBeat Community Rating for Immune Design Corp. (NASDAQ IMDZ)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about Immune Design Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immune Design Corp. (NASDAQ:IMDZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $16.00 (207.69% upside)
Consensus Price Target History for Immune Design Corp. (NASDAQ:IMDZ)
Price Target History for Immune Design Corp. (NASDAQ:IMDZ)
Analysts' Ratings History for Immune Design Corp. (NASDAQ:IMDZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Wells Fargo & CoDowngradeOutperform -> Market Perform$29.00 -> $10.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$18.00MediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Immune Design Corp. (NASDAQ:IMDZ)
Earnings by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Earnings History by Quarter for Immune Design Corp. (NASDAQ IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.65)($0.54)$1.50 million$0.73 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immune Design Corp. (NASDAQ:IMDZ)
2017 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.61)($0.55)($0.58)
Q2 20172($0.65)($0.60)($0.63)
Q3 20172($0.74)($0.64)($0.69)
Q4 20172($0.76)($0.66)($0.71)
(Data provided by Zacks Investment Research)


Dividend History for Immune Design Corp. (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immune Design Corp. (NASDAQ:IMDZ)
Insider Ownership Percentage: 20.70%
Institutional Ownership Percentage: 51.46%
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2017Leo GuthartMajor ShareholderBuy10,000$6.09$60,900.00View SEC Filing  
9/18/2017Leo GuthartMajor ShareholderBuy10,000$9.70$97,000.00View SEC Filing  
8/1/2017Wayne GombotzInsiderSell10,000$11.43$114,300.00View SEC Filing  
7/11/2017Lewis W ColemanDirectorBuy12,000$9.05$108,600.00View SEC Filing  
7/10/2017Lewis W ColemanDirectorBuy10,000$9.00$90,000.00View SEC Filing  
7/7/2017Lewis W ColemanDirectorBuy8,000$9.27$74,160.00View SEC Filing  
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immune Design Corp. (NASDAQ:IMDZ)
Latest Headlines for Immune Design Corp. (NASDAQ:IMDZ)
DateHeadline logoImmune Design Corp. to Post FY2018 Earnings of ($1.99) Per Share, Leerink Swann Forecasts (IMDZ) - October 20 at 5:26 PM logoImmune Design Corp. (IMDZ) Major Shareholder Acquires $60,900.00 in Stock - October 20 at 1:16 PM logoImmune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma - October 20 at 12:07 AM logoIs Immune Design Corp (IMDZ) Undervalued? - October 20 at 12:07 AM logoRelative Strength Alert For Immune Design - October 19 at 5:02 AM logoImmune Design continues freefall, down 20% - October 19 at 5:02 AM logoImmune Design Corp. (IMDZ) Downgraded by Wells Fargo & Company - October 17 at 1:34 PM logoImmune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients - October 16 at 8:37 PM logoETFs with exposure to Immune Design Corp. : October 9, 2017 - October 9 at 7:52 PM logoImmune Design Corp. (IMDZ) Given Consensus Recommendation of "Buy" by Analysts - October 9 at 2:42 AM logoImmune Design Corp. :IMDZ-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 - October 6 at 11:08 PM logoImmune Design Corp. (IMDZ) Expected to Post Quarterly Sales of $620,000.00 - October 5 at 1:46 AM logo-$0.63 Earnings Per Share Expected for Immune Design Corp. (IMDZ) This Quarter - October 3 at 10:20 PM logoReviewing ProQR Therapeutics N.V. (PRQR) & Immune Design Corp. (IMDZ) - September 25 at 10:30 PM logoImmune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting - September 25 at 9:39 AM logoReviewing Immune Design Corp. (IMDZ) & The Competition - September 25 at 12:26 AM logoImmune Design Corp. (IMDZ) Major Shareholder Leo Guthart Acquires 10,000 Shares - September 22 at 4:36 PM logoComparing Calithera Biosciences (CALA) & Immune Design Corp. (IMDZ) - September 22 at 4:26 PM logo Analysts Anticipate Immune Design Corp. (IMDZ) Will Announce Quarterly Sales of $620,000.00 - September 17 at 11:48 AM logoImmune Design Corp. (IMDZ) Given Average Rating of "Buy" by Brokerages - September 14 at 10:22 PM logoRoyal Bank Of Canada Begins Coverage on Immune Design Corp. (IMDZ) - September 14 at 9:50 PM logoCompany Spotlight: Immune Design - September 9 at 3:54 AM logoNew Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response - September 8 at 10:53 PM logoWhy Is Immune Design (IMDZ) Down 6.8% Since the Last Earnings Report? - September 8 at 10:53 PM logoImmune Design to Present at Upcoming Investor Conferences in September - September 1 at 8:14 PM logoInterim data positive for Immune Design's prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5% - September 1 at 5:54 AM logoImmune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress - August 31 at 6:11 AM logoHolding for Harvey - August 30 at 1:16 AM logo Immune Design Corp. (IMDZ) Given Consensus Rating of "Strong Buy" by Brokerages - August 28 at 8:10 PM logoAnalysts Issue Forecasts for Immune Design Corp.'s Q3 2017 Earnings (IMDZ) - August 28 at 1:20 AM logo-$0.65 EPS Expected for Immune Design Corp. (NASDAQ:IMDZ) This Quarter - August 9 at 7:52 AM logoJefferies Group Equities Analysts Reduce Earnings Estimates for Immune Design Corp. (IMDZ) - August 7 at 7:50 AM logoLeerink Swann Weighs in on Immune Design Corp.'s Q3 2017 Earnings (NASDAQ:IMDZ) - August 7 at 7:40 AM logoJefferies Group Comments on Immune Design Corp.'s FY2021 Earnings (NASDAQ:IMDZ) - August 4 at 8:00 PM logoInsider Selling: Immune Design Corp. (NASDAQ:IMDZ) Insider Sells 10,000 Shares of Stock - August 3 at 9:04 PM logoImmune Design's (IMDZ) CEO Carlos Paya on Q2 2017 Results - Earnings Call Transcript - August 3 at 7:58 PM logoEdited Transcript of IMDZ earnings conference call or presentation 2-Aug-17 8:30pm GMT - August 3 at 7:58 PM logoImmune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2 - August 3 at 7:58 PM logoImmune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 2 at 11:22 PM logoImmune Design reports 2Q loss - August 2 at 11:22 PM logoWhat's in the Cards for Immune Design (IMDZ) in Q2 Earnings? - July 31 at 7:14 PM logoWhat's in the Cards for Immune Design (IMDZ) in Q2 Earnings? - July 31 at 7:14 PM logoImmune Design Corp. (IMDZ) Scheduled to Post Earnings on Wednesday - July 27 at 12:15 PM logoImmune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update - July 26 at 8:06 PM logoAnalysts Anticipate Immune Design Corp. (NASDAQ:IMDZ) to Announce ($0.65) EPS - July 24 at 11:08 AM logoInsider Buying: Immune Design Corp. (NASDAQ:IMDZ) Director Purchases 12,000 Shares of Stock - July 12 at 8:18 PM logoLewis W. Coleman Buys 10,000 Shares of Immune Design Corp. (NASDAQ:IMDZ) Stock - July 12 at 8:16 PM logo3 Things In Biotech You Should Learn Today: July 11, 2017 - July 11 at 11:48 PM logoTuesday 7/11 Insider Buying Report: DLTR, IMDZ - July 11 at 11:48 PM logoImmune Design Corp. (NASDAQ:IMDZ) Director Lewis W. Coleman Purchases 8,000 Shares - July 10 at 10:58 PM



Immune Design Corp. (IMDZ) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.